All the classic signs were there seven years ago, but Carol Massaro didn’t pick up on them. Her husband’s missteps seemed more funny than cause for concern.
Joe, who’d always been very friendly with waitstaff, began asking waitresses way too personal questions.
“He’d say, ’How are you?’ as usual,” Mrs. Massaro recalls, “but then he’d add, ‘How much do you weigh? or ‘How tall are you?’ ”
A consummate businessman who headed one of the city’s largest construction companies, Mr. Massaro also began having trouble recalling familiar names and places. On car trips to Downtown from the couple’s condo in Shadyside — a drive he’d done hundreds of times as CEO of Massaro Corp. — he’d ask whether he should turn right here, or left. And he struggled with finding the right words, telling his wife how happy he was their home was so close to the “umbrella,” or elevator.
Then one afternoon in 2008, Ms. Massaro came home from the beauty shop to find her husband missing. When he appeared at the door hours later, he admitted he gotten hopelessly lost trying to find Towne Drugs in Aspinwall.
Doctors at the University of Pittsburgh Alzheimer’s Disease Research Center at UPMC Montefiore confirmed early-onset Alzheimer’s disease. Mr. Massaro, 72, was one of the estimated 250,000 people in the U.S. with the early version. He’d probably had it for at least five years. “My heart sank,” she says.
Read More
In the years since, the physical and emotional demands of caring for Mr. Massaro 24/7 has taken its toll on the family; two years ago, with him no longer able to walk or talk, they hired full-time caregivers. But it’s also given his wife purpose: to help find a cure for the disease, which by 2050 will affect an estimated 13.8 million Americans.
On June 28, Mrs. Massaro is holding a second annual fundraiser for the Joseph A. Massaro Jr. Alzheimer’s Research Fund, which she established last year through the Pittsburgh Foundation. Along with cocktails and dinner at LeMont Restaurant on Mount Washington, Time for a Cure will include a performance by Verdi mezzo-soprano Marianne Cornetti. Tickets cost $500.
“What it does to a person is horrible,” she explains, “and I realized early on that there’s no medicine or cure.” Researchers can’t seem to agree on what causes the disease. “Everyone has a different theory.”
Raising money for research, she thought, would help those who have no option but to ride it out.
Last year’s inaugural effort, which included a reception at Oakmont Country Club, “astounded” Mrs. Massaro, who underwrote all expenses. “I thought, ‘If I can just get 100 people to donate a thousand dollars, we’d have something,” she says. She ended up raising $350,000. Her goal this year is at least $150,000.
Mrs. Massaro’s efforts are different from a lot of other fundraising efforts because she’s keeping the money in Pittsburgh. Not only because all of her contributors have ties to the city, but “we also have wonderful resources here,” she says.
To that end, the fund in February awarded its first $75,000 research grant to Edward Burton, associate professor of neurology in Pitt’s department of neurology. In his work as a movement disorders specialist, Dr. Burton has studied the connection between tau proteins — found in “tangles” in the brains of Alzheimer’s patients, causing nerve cell death — and progressive supranuclear palsy, a brain disorder with symptoms similar to Parkinson’s disease. He and his team have developed a novel model using really tiny zebrafish — babies in their first week of life — to study the molecular events that lead to dementia.
It’s not as weird as it sounds. As vertebrate animals, zebrafish share more than 70 percent of their genes with humans, including many of those thought to be important in neurological disease such as tau, Dr. Burton said. In addition, their brains are organized the same way as humans, including the parts characteristically affected in Alzheimer’s.
Because they have transparent embryos that develop outside the body, zebrafish are ideal for studying under the microscope. Also, their genetic material can easily be manipulated. Dr. Burton and his team have been able to create genetically modified embryos that harbor a copy of the human tau gene that has a mutation linked to dementia in humans — and label specific cells with proteins that light up a particular way under the microscope.
Another plus: Zebrafish have lots of babies. So when Dr. Burton’s team make the fish sick with an aquatic version of Alzheimer’s, they can screen large numbers against the chemicals they think might prevent them from getting ill.
Fifteen years ago, researchers couldn’t identify all the proteins that now are the hallmark of Alzheimer’s, “and we certainly didn’t have the tools for discovery,” Dr. Burton said. He’s hoping his novel research will help develop drugs to treat or stop the disease. “The field has moved on so much since then, that I feel there’s a real possibility we’ll solve Alzheimer’s in our lifetime.”
Funding for research, he notes, is very difficult to get through conventional means such as federal grants because you have to show proof of concept that your experimental approach would work, “and that’s what we’re still testing out.”
While a $75,000 grant may seem modest against the millions contributed to Alzheimer’s research, for Dr. Burton it’s significant.
“We’ll be able to run the project for a year, and work out how to utilize our novel zebrafish tau models for drug discovery,” he says.
It also comes with a sense of responsibility.
“When you’re funded by the government, you’re responsible to taxpayers,” he says. “With Carol, it’s more direct. There’s a very specific patient that motivates the research, and for her it’s very personal.”
For more information on, or to donate to, the Joseph A. Massaro Jr. Alzheimer’s Research Fund, go to pittsburghfoundation.org/Massaro. For tickets to Time for a Cure, call 412-683-1121.
Gretchen McKay: gmckay@post-gazette.com, 412-263-1419 or on Twitter @gtmckay.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.